British multinational pharmaceutical and biotech company GSK announced a three-year agreement with a $70 million initial payment to expand its access to Tempus' AI-powered data library, including its de-identified patient data.
GSK says the collaboration will allow it to leverage the U.S.-based company's library to accelerate drug discovery in oncology, improve its clinical trial design,...
